Abstract 119P
Background
Gastric cancer (GC) remains the fifth most common malignancy worldwide accounting for over 1 million new cases and an estimated 769,000 deaths by 2020. Nearly 40% of the global GC cases occur in China, and the 5-year overall survival rate is less than 50%. Lymph node metastases (LNM) is an independent risk factor for prognosis and determines which treatments can be used in GC. LNM plays a crucial gateway role in cancer spread, but the underlying roles of LNM remain controversial, and there is no worldwide consensus. Therefore, the aim of this study was to investigate the clinical perspective and significance of LNM in GC via a retrospective study.
Methods
This study was performed on 129 patients who had gastric cancer with lymphadenectomy for the radical cure, whose specimens were obtained during surgery. Dissected lymph nodes were collected in groups and histopathological studies were performed to detect the lymph node metastasis and metastatic lymph node ratio (MLR). We also analyzed the relationships between rates of lymph node metastasis and tumor diameters, tumor localization, infiltrating depth, histological category, Borrmann typing, and so on.
Results
Among 129 patients with gastric cancer, lymph node metastases were found in 80 patients (62.02%) with a total collection of 3295 lymph nodes and an average of 25.54 lymph nodes per patient. The number of lymph nodes with metastasis was 889. Lymph node metastasis was associated with tumor size, the depth of invasion, Borrmann type, location and histological type. There were correlations between the total number of lymph nodes from 129 gastric cancer patients, metastatic lymph node numbers and MLR. Analysis of the survival curve showed that the survival time and rate had a negative correlation with the TNM stage and MLR.
Conclusions
According to the clinical and pathological factors, the characteristics of lymph node metastasis by groups and stations in different areas, and properly choosing and extending the extent of lymph node resection, the objective of the radical cure for gastric cancer could be achieved individually when radical lymphadenectomy is performed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Technology Innovation Guidance Special Program of Shaanxi Province (2022QFY01-08), Key Research and Development Program of Shaanxi Province (2021SF-288), Natural Science Basic Research Program of Shaanxi Province (2020JQ-950, 2022JM-570), Health Research Program of Shaanxi Province (2022D002).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
108P - A meta-analysis of PD-1 inhibitors for the treatment of advanced esophageal squamous cell carcinoma in second-line setting
Presenter: Barinder Singh
Session: Poster viewing 02
109P - Economic evaluation of second-line treatment for patients with esophageal squamous cell carcinoma: A systematic review
Presenter: Gagandeep Kaur
Session: Poster viewing 02
110P - Neutrophil to lymphocyte ratio as a predictor of poor prognosis in advanced esophageal cancer
Presenter: Chaichana Chantharakhit
Session: Poster viewing 02
111P - Bicentric real-life analysis of the molecular portrait of patients with early onset metastatic biliary tract cancer
Presenter: Theresa Schmalfuss
Session: Poster viewing 02
112P - Prognostic role of sarcopenia before neoadjuvant chemoradiotherapy in patients with esophageal cancer: A retrospective study
Presenter: Mastaneh Sanei
Session: Poster viewing 02
113P - Brain metastases in esophageal cancer patients who have been treated with neoadjuvant immunotherapy plus chemotherapy: An inconsiderable complication
Presenter: Jun Liu
Session: Poster viewing 02
114P - Risk factors for oesophageal fistula: A life-threatening complication of treatment for oesophageal cancer
Presenter: Reo Omori
Session: Poster viewing 02
115P - Human epidermal growth factor receptor-2 (HER-2) expression status in patients with cholangiocarcinoma
Presenter: Thanit Imemkamon
Session: Poster viewing 02
116P - Spleen as an organ at risk (OAR) in adjuvant chemoradiotherapy of gastric cancer: Retrospective dosimetric single institutional experience
Presenter: Preethi Shetty
Session: Poster viewing 02
117P - Immunoprofile of adenosquamous carcinoma in gastric cancer
Presenter: Cheng-Han Wu
Session: Poster viewing 02